Pazopanib for the treatment of patients with advanced renal cell carcinoma

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 95-105

  Lang, Joshua M ^a   Harrison, Michael R ^a  

^a University of Wisconsin Health   (United States)

Author keywords

GW786034; Pazopanib; Renal cell carcinoma; Tyrosine kinase inhibitor; VEGF; VEGFR TKI

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; LAPATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; VOTRIENT;

ADVANCED CANCER; AREA UNDER THE CURVE; ASTHENIA; BLEEDING; BRAIN ISCHEMIA; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPIGMENTATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART ATRIUM THROMBOSIS; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIPID DIET; LIVER FUNCTION; LIVER TOXICITY; LOW FAT DIET; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PERITONITIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RASH; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 78649356814     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S4088     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Linehan WM WM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003 Dec;170(6 Pt 1):2163-2172.
3. Kim WY, Kaelin WG. Role of VHL Gene Mutation in Human Cancer. J Clin Oncol. 2004;22(24):4991-5004.
4. Linehan WM, Zbar B, Bates BE, Zelefsky MJ, Yang JC. Cancer of the Kidney and Ureter. In: deVita VT HS, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins. 2001:1362-1396.
5. Cohen HT, McGovern FJ. Renal-Cell Carcinoma. N Engl J Med. 2005; 353(23):2477-2490.
6. Fisher RI RS, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6 Suppl 1:S55-S57.
7. Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009;115(S10):2306-2312.
8. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. 1994;7(1):85-90.
9. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. The Journal of Pathology. 2002; 196(2):186-193.
10. Gallou C, Joly D, Méjean A, et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Human Mutation. 1999;13(6):464-475.
11. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9(12):1793-805.
12. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. J Clin Oncol. 2008;26(22):3743-3748.
13. Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. European Journal of Cancer. 2001;37(17):2199-2203.
14. Wechsel HWBK, Feil G, Loeser W, Lahme S, Petri E. Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res. 1999 Mar-Apr; 19(2C):1537-1540.
15. Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncology. 2009;5(5):703-712.
16. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cellular and Molecular Life Sciences. 2006;63(5):601-615.
17. Yang JC, Haworth L, Sherry RM, et al. A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. N Engl J Med. 2003;349(5):427-434.
18. Escudier B, Bellmunt J, Negrier S, et al. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol. 2010;28(13):2144-2150.
19. Rini BI, Halabi S, Rosenberg JE, et al. Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
20. Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol. 2003;22:192.
21. Strumberg D, Richly H, Hilger RA, et al. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J Clin Oncol. 2005;23(5):965-972.
22. Rini BI WG, Hudes G, Stadler WM, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol. 2007; 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (Jun 20 Supplement):5032.
23. Hurwitz HI, Dowlati A, Saini S, et al. Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clinical Cancer Research. 2009;15(12): 4220-4227.
24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007;356(2):125-134.
25. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2007;356(2):115-124.
26. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
27. Limvorasak S, Posadas EM. Pazopanib: therapeutic developments. Expert Opin Pharmacother. 2009;10(18):3091-3102.
28. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs Today (Barc). 2009;45(9):651-661.
29. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics. 2007;6(7):2012-2021.
30. Votrient (pazopanib) [package insert]. Research Triangle Park NG.
31. Shibata SLJ, Chung VM, Lenz H, et al. A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). J Clin Oncol. 28:15s, (Suppl; abstr 2571). 2010.
32. Dejonge MSS, Verweij J, Collins TS, et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Onco. 24:142s, (Suppl; abstr 3088). 2006.
33. Tan ARJS, Dowlati A, Levinson K, et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J Clin Oncol. 2008;26 (May 20 Suppl; abstr 3552).
34. Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2010;28(3):475-480.
35. Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol. 2010; 28:15s, (Suppl; abstr 3048).
36. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2010;28(6):1061-1068.
37. Sternberg CN. Pazopanib in renal cell carcinoma. Clin Adv Hematol Oncol. 2010 Apr;8(4):232-233.
38. Xu C-F, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. 2010;102(9): 1371-1377.
39. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma. J Clin Oncol. 1999;17(8):2530.
40. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients with Previously Untreated Metastatic Renal Cell Carcinoma. J Clin Oncol. 2005;23(4):832-841.
41. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 2008;372(9637):449-456.
42. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2007;356(22):2271-2281.
43. DePrimo S, Bello C, Smeraglia J, et al. Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer. Proc Am Assoc Cancer Res. 2005;46:108.
44. Escudier B, Szczylik C, Hutson TE, et al. Randomized Phase II Trial of First-Line Treatment with Sorafenib Versus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27(8):1280-1289.